Compare HUBG & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBG | AUPH |
|---|---|---|
| Founded | 1971 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 1996 | 2014 |
| Metric | HUBG | AUPH |
|---|---|---|
| Price | $35.84 | $16.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $42.83 | $17.25 |
| AVG Volume (30 Days) | ★ 1.0M | 894.1K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | ★ 1.34 | 0.53 |
| Revenue | ★ $3,946,390,000.00 | $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | $2.88 | $15.74 |
| P/E Ratio | ★ $26.90 | $30.38 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $32.90 | $10.34 |
| 52 Week High | $53.26 | $19.25 |
| Indicator | HUBG | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 34.24 | 51.38 |
| Support Level | $32.90 | $14.97 |
| Resistance Level | $44.40 | $16.40 |
| Average True Range (ATR) | 1.53 | 0.34 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 14.71 | 28.06 |
Hub Group ranks among the largest providers of rail intermodal service. Approximately 60% of consolidated revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset-light truck brokerage operations along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub often makes tuck-in acquisitions that expand its brokerage, last-mile, and dedicated offerings.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.